Expansion opportunities HelloBetter has shown international growth, launching HelloGina in the US and forming partnerships like Mein MentalHealthCoach with Generali in Germany. Sales teams can target health insurers, employers, and digital health platforms in both Europe and the US to expand distribution of DTx for mental health and sexual wellness.

FDA recognition Breakthrough Device Designation from the FDA for HelloBetter Panic signals regulatory credibility and faster access pathways. This can be leveraged to engage US healthcare systems, payers, and risk-bearing entities seeking validated digital therapeutics with strong evidence.

Strong evidence base With 33 randomized controlled trials and a broad catalog of DiGA-ready programs in Germany, HelloBetter can position as a trusted DTx partner for payer-led initiatives, hospital networks, and employer health programs seeking evidence-backed mental health solutions.

Financial momentum Recent funding rounds totaling over €31 million and multiple cash and media-for-equity investments indicate growing investor confidence. This can support scaled business development efforts, co-marketing, and joint ventures with strategic partners in health tech and life sciences.

Enterprise partnerships Recent collaborations with Generali and the focus on B2B digital mental health services highlight a market opportunity in employer and insurer channels. Target midsize to large employers, benefits administrators, and health insurers seeking scalable, regulatory-compliant DTx solutions.